677
Views
3
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Unsustained response to brentuximab as single agent therapy in a patient with CD30 positive angiosarcoma

, , &
Pages 251-253 | Received 09 Feb 2015, Accepted 21 Feb 2015, Published online: 27 Apr 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Michele Merli, Andrea Ferrario, Margherita Maffioli, Cecilia Olivares, Alessandra Stasia, Luca Arcaini & Francesco Passamonti. (2016) New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. Expert Review of Hematology 9:8, pages 767-780.
Read now

Articles from other publishers (2)

M.E. Weidema, Y.M.H. Versleijen-Jonkers, U.E. Flucke, I.M.E. Desar & W.T.A. van der Graaf. (2019) Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease. Critical Reviews in Oncology/Hematology 138, pages 120-131.
Crossref
Garrett K. Berger, Kevin Gee, Cassandra Votruba, Ali McBride & Faiz Anwer. (2017) Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature. Critical Reviews in Oncology/Hematology 113, pages 8-17.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.